Abstract
Models developed for the study of asthma mechanisms can be used to investigate new compounds with pharmacological activity against this disease. The increasing number of compounds requires a preclinical evaluation before starting the application in humans. Preclinical evaluation in animal models reduces the number of clinical trials positively impacting in the cost and in safety. In this chapter, three protocols for the study of drugs are shown: a model to investigate corticoids as a classical treatment of asthma; a protocol to test the effects of retinoic acid (RA) on asthma; and a mouse model to test new therapies in asthma as monoclonal antibodies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Holgate ST, Broided D (2003) New targets for allergic rhinitis-a disease of civilization. Nat Rev Drug Discov 2:902–914
Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 157:1–53
Marielle M, Ruffie C, Periquet B et al (2007) Liposomal retinoic acids modulate asthma manifestations in mice. J Nutr Dis 0022-3166/07:2731-2736
Biesalski HK (2003) The significance of vitamin A for the development and function of the lung. Forum Nutr 6:37–40
Denburg JA, Sehmi R, Upham J et al (1999) Regulation of IL-5 and IL-5 receptor expression in the bone marrow of allergic asthmatics. Int Arch Allergy Immunol 118:101–103
Denburg JA, Sehmi R, Upham J (2001) Regulation of IL-5 receptor on eosinophil progenitors in allergic inflammation: role of retinoic acid. Int Arch Allergy Immunol 124:246–248
Goettsch W, Hattori Y, Sharma RP (1992) Adjuvant activity of all-trans-retinoic acid in C57Bl/6 mice. Int J Immunopharmacol 14:143–150
Rambasek TE, Lang DM, Kavuru MS et al (2004) Omalizumab: where does it fit into current asthma management? Cleve Clin J Med 71:251–261
Curtiss F (2005) Selectivity and specificity are the keys to cost-effective use of Omalizumab for allergic asthma. J Manag Care Pharm 11:774–776
Polosa R, Casale T et al (2012) Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discov Today 17(11/12):591–599
Larche M, Akdis CA, Valenta R (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6:761–771
Valenta R, Campana R, Marth K et al (2012) Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 272:144–157
Acknowledgments
This work was supported by grants of the Junta de Castilla y León ref. GRS1047/A/14 and GRS1189/A/15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Marqués-García, F., Marcos-Vadillo, E. (2016). Mouse Models Applied to the Research of Pharmacological Treatments in Asthma. In: Isidoro García, M. (eds) Molecular Genetics of Asthma. Methods in Molecular Biology, vol 1434. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3652-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3652-6_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3650-2
Online ISBN: 978-1-4939-3652-6
eBook Packages: Springer Protocols